Aethlon Medical, Inc. (AEMD)

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its first quarter ended June 30, 2022, at 4:15 p.m. EST on Tuesday, August 9, 2022.

• 
  Pyxis Tankers Announces Record Financial Results for the Three Months Ended June 30, 2022

  GlobeNewswire
• 
  Netcapital Announces Fiscal Year 2022 Financial Results

  Business Wire

Aethlon Medical Announces Publication of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding of Seven COVID-19 Variants

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced the publication of a peer-reviewed journal article in PLOS ONE. The article, titled "Removal of Clinically Relevant SARS-CoV-2 Variants by An Affinity Resin Containing Galanthus nivalis Agglutinin," contains data demonstrating that the proprietary GNA affinity resin of the Aethlon Hemopurifier® efficiently captur

Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol of its ongoing clinical trial investigating the Aethlon Hemopurifier® for patients with severe COVID-19. The newly approved protocol amendment eliminates the inclusion criteria that patients must have a dialysis catheter in